Jennifer L Schutzman
Overview
Explore the profile of Jennifer L Schutzman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turner N, Im S, Saura C, Juric D, Loibl S, Kalinsky K, et al.
N Engl J Med
. 2024 Oct;
391(17):1584-1596.
PMID: 39476340
Background: Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by ) that also promotes the...
2.
Jhaveri K, Accordino M, Bedard P, Cervantes A, Gambardella V, Hamilton E, et al.
J Clin Oncol
. 2024 Sep;
42(33):3947-3956.
PMID: 39236276
Purpose: To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in...
3.
Sisoudiya S, Houle A, Fernando T, Wilson T, Schutzman J, Lee J, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):153.
PMID: 39033203
Racial/ethnic disparities mar NSCLC care and treatment outcomes. While socioeconomic factors and access to healthcare are important drivers of NSCLC disparities, a deeper understanding of genetic ancestry-associated genomic landscapes can...
4.
Choi Y, Dharia N, Jun T, Chang J, Royer-Joo S, Yau K, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3788-3797.
PMID: 38995268
Purpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS...
5.
Desai J, Alonso G, Kim S, Cervantes A, Karasic T, Medina L, et al.
Nat Med
. 2023 Dec;
30(1):271-278.
PMID: 38052910
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent...
6.
Sacher A, LoRusso P, Patel M, Miller Jr W, Garralda E, Forster M, et al.
N Engl J Med
. 2023 Aug;
389(8):710-721.
PMID: 37611121
Background: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study, we evaluated divarasib administered orally once...
7.
Lee J, Sivakumar S, Schrock A, Madison R, Fabrizio D, Gjoerup O, et al.
NPJ Precis Oncol
. 2022 Dec;
6(1):91.
PMID: 36494601
Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered samples from 426,706 adult patients with solid...
8.
Dickmann L, Schutzman J
Oncologist
. 2017 Dec;
23(2):243-246.
PMID: 29259072
Many approved drugs demonstrate different pharmacokinetics, pharmacodynamics, and/or safety across racial and ethnic groups. The primary objective of the current study was to summarize the racial and ethnic makeup of...
9.
Soria J, Adjei A, Bahleda R, Besse B, Ferte C, Planchard D, et al.
Eur J Cancer
. 2017 Oct;
86:186-196.
PMID: 28992562
Aim: The phosphatidylinositol 3-kinase (PI3K) pathway is a potential therapeutic target in non-small cell lung cancer (NSCLC). This study aimed to evaluate the pan-PI3K inhibitor pictilisib in combination with first-line...
10.
Leong S, Moss R, Bowles D, Ware J, Zhou J, Spoerke J, et al.
Oncologist
. 2017 Aug;
22(12):1491-1499.
PMID: 28798270
Background: Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types. Enhanced antitumor activity may be achieved through combined inhibition...